Steensma, David P.
Ajax Therapeutics,
United States
2025 Rank: 11308
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 227 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 11308 | 12144 |
| Total Cites | 1490 | 1671 |
| H-index | 17 | 17 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 98 | 98 |
| Total Cites to Single Authored Papers | 80 | 83 |
| Number of Single+First Authored Papers | 205 | 205 |
| Total Cites to Single+First Authored Papers | 365 | 384 |
| Number of Single+First+Last Authored Papers | 332 | 332 |
| Total Cites to Single+First+Last Authored Papers | 490 | 515 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1125 | 1221 |
| Ratio of Total Citations to Distinct Citing Papers | 1.32 | 1.37 |
| Self-Citation Percentage |
10.83%
|
|
Steensma, David P.
Ajax Therapeutics,
United States
2024 Rank: 7890
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 186 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 7890 | 7186 |
| Total Cites | 1638 | 1935 |
| H-index | 19 | 21 |
| Hm-index | 7 | 8 |
| Number of Single Authored Papers | 94 | 94 |
| Total Cites to Single Authored Papers | 99 | 101 |
| Number of Single+First Authored Papers | 208 | 208 |
| Total Cites to Single+First Authored Papers | 435 | 467 |
| Number of Single+First+Last Authored Papers | 333 | 333 |
| Total Cites to Single+First+Last Authored Papers | 557 | 599 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1169 | 1283 |
| Ratio of Total Citations to Distinct Citing Papers | 1.40 | 1.51 |
| Self-Citation Percentage |
15.35%
|
|
Steensma, David P.
Novartis Institutes for BioMedical Research, Inc.,
United States
2023 Rank: 7916
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 196 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 7916 | 6978 |
| Total Cites | 1606 | 1925 |
| H-index | 18 | 20 |
| Hm-index | 7 | 8 |
| Number of Single Authored Papers | 92 | 92 |
| Total Cites to Single Authored Papers | 121 | 122 |
| Number of Single+First Authored Papers | 201 | 201 |
| Total Cites to Single+First Authored Papers | 428 | 459 |
| Number of Single+First+Last Authored Papers | 325 | 325 |
| Total Cites to Single+First+Last Authored Papers | 552 | 599 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1174 | 1308 |
| Ratio of Total Citations to Distinct Citing Papers | 1.37 | 1.47 |
| Self-Citation Percentage |
16.57%
|
|
Steensma, David P.
Novartis Institutes for BioMedical Research, Inc.,
United States
2022 Rank: 5066
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 147 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 5066 | 5005 |
| Total Cites | 1760 | 2007 |
| H-index | 21 | 23 |
| Hm-index | 8 | 8 |
| Number of Single Authored Papers | 92 | 92 |
| Total Cites to Single Authored Papers | 144 | 147 |
| Number of Single+First Authored Papers | 196 | 196 |
| Total Cites to Single+First Authored Papers | 477 | 501 |
| Number of Single+First+Last Authored Papers | 317 | 317 |
| Total Cites to Single+First+Last Authored Papers | 617 | 652 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1269 | 1378 |
| Ratio of Total Citations to Distinct Citing Papers | 1.39 | 1.46 |
| Self-Citation Percentage |
12.31%
|
|
Steensma, David P.
Dana-Farber Cancer Institute,
United States
2021 Rank: 5624
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 149 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 5624 | 5013 |
| Total Cites | 2236 | 2606 |
| H-index | 23 | 27 |
| Hm-index | 11 | 11 |
| Number of Single Authored Papers | 91 | 91 |
| Total Cites to Single Authored Papers | 226 | 238 |
| Number of Single+First Authored Papers | 190 | 190 |
| Total Cites to Single+First Authored Papers | 647 | 691 |
| Number of Single+First+Last Authored Papers | 310 | 310 |
| Total Cites to Single+First+Last Authored Papers | 842 | 905 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1669 | 1839 |
| Ratio of Total Citations to Distinct Citing Papers | 1.34 | 1.42 |
| Self-Citation Percentage |
14.20%
|
|
Steensma, David P.
Dana-Farber Cancer Institute,
United States
2020 Rank: 7770
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 188 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 7770 | 6718 |
| Total Cites | 1425 | 1730 |
| H-index | 17 | 20 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 88 | 88 |
| Total Cites to Single Authored Papers | 147 | 161 |
| Number of Single+First Authored Papers | 182 | 182 |
| Total Cites to Single+First Authored Papers | 457 | 513 |
| Number of Single+First+Last Authored Papers | 294 | 294 |
| Total Cites to Single+First+Last Authored Papers | 578 | 654 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1091 | 1237 |
| Ratio of Total Citations to Distinct Citing Papers | 1.31 | 1.40 |
| Self-Citation Percentage |
17.63%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.